Neurocrine Biosciences (Nasdaq: NBIX) has announced positive results from its Phase IV KINECT-PRO study, showing that Ingrezza (valbenazine) provided meaningful and sustained benefits for patients ...

It is important for clinicians to understand the causes and symptoms of tardive dyskinesia to avoid common misdiagnoses and ensure effective management.

It is important for clinicians to understand the causes and symptoms of tardive dyskinesia to avoid common misdiagnoses and ensure effective management.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q4 2024 Earnings Call Transcript February 6, 2025 Neurocrine Biosciences, Inc. misses on earnings expectations. Reported EPS is $1 EPS, expectations were ...

Neurocrine Biosciences Q4 EPS of $1.69 beat estimates, while revenue missed consensus. Ingrezza sales rose 23% to $615 million. 2025 Ingrezza sales guidance fell short of Street estimate.

Q4 revenue was $627.7 million, slightly below the $629 million estimate. Ingrezza remains the main revenue driver, with a 23% increase in quarterly sales to $615 million. Neurocrine Biosciences ...

As with other drugs, Ingrezza (valbenazine) can cause side effects, such as drowsiness and parkinsonism. If you are unable to tolerate Ingrezza’s side effects, talk with your doctor or ...